Valuation Update With 7 Day Price Move • 14m
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to CN¥161, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 46x in the Life Sciences industry in China. Total returns to shareholders of 119% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥227 per share. Annuncio • Aug 05
Wuxi Apptec Co., Ltd. Raises Full Year Guidance for the Fiscal Year 2026 WuXi AppTec Co., Ltd. raised full year guidance for the fiscal year 2026. For the period, the company's total revenue target raised to RMB 58.5 billion - RMB 60.5 billion (previously RMB 51.3 billion - RMB 53.0 billion), with Continuing Operations revenue growing 35-39% YoY (previously 18-22%). Annuncio • Jun 30
WuXi AppTec Co., Ltd. to Report First Half, 2026 Results on Aug 04, 2026 WuXi AppTec Co., Ltd. announced that they will report first half, 2026 results on Aug 04, 2026 Valuation Update With 7 Day Price Move • Jun 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥118, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 35x in the Life Sciences industry in China. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥175 per share. Declared Dividend • May 27
Dividend of CN¥1.58 announced Shareholders will receive a dividend of CN¥1.58. Ex-date: 29th May 2026 Payment date: 29th May 2026 Dividend yield will be 1.9%, which is higher than the industry average of 1.4%. Sustainability & Growth Dividend is well covered by both earnings (30% earnings payout ratio) and cash flows (50% cash payout ratio). The dividend has increased by an average of 34% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 27% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Board Change • May 20
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 5 highly experienced directors. 5 independent directors (7 non-independent directors). Independent Non-Executive Director Jeff Leng was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Mar 30
WuXi AppTec Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 WuXi AppTec Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Annuncio • Mar 26
Wuxi Apptec Co., Ltd. Proposes Cash Dividend for the Year 2026 WuXi AppTec Co., Ltd. proposed cash dividend distribution plan totaling a record RMB 5.7 billion in 2026. Annuncio • Mar 24
WuXi AppTec Co., Ltd., Annual General Meeting, Apr 28, 2026 WuXi AppTec Co., Ltd., Annual General Meeting, Apr 28, 2026, at 14:00 China Standard Time. Location: sheraton shanghai waigaoqiao hotel, 28 jilong road, pilot free trade zone, shanghai., China Annuncio • Jan 12
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Full Year 2025 WuXi AppTec Co., Ltd. provided earnings guidance for the full year 2025. For the year, total revenue is expected to be approximately RMB 45.46 billion, representing a year-over-year increase of approximately 15.8%, with revenue from Continuing Operations growing by approximately 21.4% year-over-year. Net profit after deducting non-recurring items is expected to be approximately RMB 13.24 billion, representing a year-over-year increase of approximately 32.6%. Net profit attributable to the owners of the Company is expected to be approximately RMB 19.15 billion. This represents a year-over-year increase of approximately 102.6%, including the investment income from sale of a partial interest in an associate and from divestiture of certain business. Basic earnings per share for the full year of 2025 is expected to be approximately RMB 6.70, representing a year-over-year increase of approximately 104.3%. Annuncio • Dec 26
WuXi AppTec Co., Ltd. to Report Fiscal Year 2025 Results on Mar 24, 2026 WuXi AppTec Co., Ltd. announced that they will report fiscal year 2025 results on Mar 24, 2026 Annuncio • Oct 27
WuXi AppTec Co., Ltd. Raises Earnings Guidance for They Full Year 2025 WuXi AppTec Co., Ltd. raised earnings guidance for they full year 2025 . For the year, company expected full-year total revenue of RMB 43.5 to RMB 44.0 billion, up from the prior RMB 42.5 Billion to RMB 43.5 billion. Annuncio • Sep 30
WuXi AppTec Co., Ltd. to Report Q3, 2025 Results on Oct 27, 2025 WuXi AppTec Co., Ltd. announced that they will report Q3, 2025 results on Oct 27, 2025 Annuncio • Sep 22
WuXi AppTec Co., Ltd. Implements First Interim Dividend Plan WuXi AppTec Co., Ltd. implemented its first interim dividend plan, distributing a total of RMB 1.03 billion in cash dividends. Annuncio • Aug 07
WuXi AppTec Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 7.695126 billion. WuXi AppTec Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 7.695126 billion.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 73,800,000
Price\Range: HKD 104.27
Transaction Features: Subsequent Direct Listing Annuncio • Jul 31
WuXi AppTec Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 7.695126 billion. WuXi AppTec Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 7.695126 billion.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 73,800,000
Price\Range: HKD 104.27
Transaction Features: Subsequent Direct Listing Annuncio • Jul 10
Wuxi Apptec Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2025 to June 30, 2025 WuXi AppTec Co., Ltd. provided earnings guidance for the period from January 1, 2025 to June 30, 2025. For the year, The revenue of the Company was expected to be approximately RMB 20,799.28 million for the Current Period, representing a year-over-year increase of approximately 20.64%, revenue from continuing operations representing a year-over-year increase of approximately 24.24%. The net profit attributable to the owners of the Company after deducting non-recurring gain or loss items was expected to be approximately RMB 5,582.13 million for the Current Period, representing a year-over-year increase of approximately 26.47%. The net profit attributable to the owners of the Company was expected to be approximately RMB 8,560.88 million for the Current Period, representing a year-over-year increase of approximately 101.92%; the total profit of the Company was expected to be approximately RMB 9,907.42 million for the Current Period, representing a year-over-year increase of approximately 96.20%; and the basic earnings per share was expected to be approximately RMB 3.01 per share for the Current Period, representing a year-over-year increase of approximately 106.16%. Annuncio • Jun 30
WuXi AppTec Co., Ltd. to Report First Half, 2025 Results on Jul 29, 2025 WuXi AppTec Co., Ltd. announced that they will report first half, 2025 results on Jul 29, 2025 Annuncio • Jun 24
WuXi AppTec Co., Ltd.(SHSE:603259) dropped from Shanghai Stock Exchange 180 Value Index WuXi AppTec Co., Ltd. has been removed from Shanghai Stock Exchange 180 Value Index . Annuncio • Apr 29
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Year 2025 WuXi AppTec Co., Ltd. provided earnings guidance for the year 2025. "The Company currently maintains its full-year guidance set at the beginning of the year 2025. The company expects revenue from Continuing Operations to grow 10%-15% in 2025. Annuncio • Mar 28
WuXi AppTec Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 WuXi AppTec Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Annuncio • Mar 26
WuXi AppTec Co., Ltd., Annual General Meeting, Apr 29, 2025 WuXi AppTec Co., Ltd., Annual General Meeting, Apr 29, 2025, at 14:00 China Standard Time. Location: sheraton shanghai waigaoqiao hotel, 28 jilong road, pilot free trade zone, shanghai China Annuncio • Dec 27
WuXi AppTec Co., Ltd. to Report Fiscal Year 2024 Results on Mar 18, 2025 WuXi AppTec Co., Ltd. announced that they will report fiscal year 2024 results on Mar 18, 2025 Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.79 (vs CN¥0.94 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.79 (down from CN¥0.94 in 3Q 2023). Revenue: CN¥10.5b (down 2.0% from 3Q 2023). Net income: CN¥2.29b (down 17% from 3Q 2023). Profit margin: 22% (down from 26% in 3Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Annuncio • Oct 05
WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom Two affiliated Chinese drug manufacturers targeted by forthcoming US national security legislation are working on sales of some of their operations, according to people familiar with the matter. WuXi AppTec Co., Ltd. (SHSE:603259) and WuXi Biologics (Cayman) Inc. (SEHK:2269) are among five China-based companies targeted by the Biosecure Act, which would ban drugmakers with US government contracts from using the Chinese groups’ services after 2032. The bipartisan bill overwhelmingly passed the House of Representatives last month and is making its way through the Senate. WuXi AppTec has put its cell and gene therapy manufacturing arm WuXi Advanced Therapies, Inc., which operates four laboratories and manufacturing facilities in Philadelphia, up for sale, according to three people familiar with the matter. Discussions have been ongoing for months and rival contract manufacturers have been approached about buying all or some of the assets. Separately, three people familiar with the situation said WuXi Biologics was working with advisers to test interest in some of its European production facilities, which management fears it may no longer need. New business in Europe has dried up in recent months, as biopharma companies with or seeking US federal contracts have become reluctant to use WuXi in light of the legislation. Revenues from European customers fell 27% in the first six months of 2024 compared to a year earlier, to RMB 1.8 billion ($260 million). WuXi Biologics told the FT it “continues to experience good business momentum. We are consistently securing new projects across all regions including the US, EU, China and the rest of Asia”. The Biosecure Act has made the pharmaceutical industry the latest sector subject to growing trade and national security tensions between the US and China after technology companies such as TikTok were targeted. Both WuXi entities, which are related but operate independently, are key cogs in the US and global pharmaceutical supply chain, playing a role in the production of AbbVie’s $3.5 billion a year cancer drug Imbruvica and Pfizer’s anti-Covid pill Paxlovid, among dozens of other medicines, according to GlobalData. More than 20 drugmakers, including AbbVie, have flagged their reliance on WuXi companies in regulatory filings this year, according to AlphaSense. Chief among WuXi Biologics’ assets being reviewed for sale are two German manufacturing facilities it bought from Bayer and spent extensively on expanding last year. WuXi Biologics also has large production facilities in Ireland. WuXi AppTec told the Financial Times it was “assessing options” for continuing its Advanced Therapies unit’s operations “in line with our priorities: our employees and the patients who need essential, time-critical and life-saving treatments”. WuXi Biologics said it “regularly conducts business reviews, with a focus on delivering a consistently high return on investment across all assets for our investors. We do not comment on market speculations”. With the Biosecure Act declaring WuXi “a biotechnology company of concern”, WuXi AppTec shares are down 14%, while those of WuXi Biologics have fallen nearly 30% this year. Cumulatively, both companies are valued at about $36 billion. People briefed on the sale processes said it was possible that the assets may not be sold. They added that WuXi AppTec and WuXi Biologics were seriously considering their options as they may no longer need as much production capacity as previously thought. WuXi Biologics may opt to keep their European facilities if existing clients decide to stick with them, as the Biosecure Act will take time to have an effect, a person said. Annuncio • Sep 30
WuXi AppTec Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 WuXi AppTec Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥47.60, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 21x in the Life Sciences industry in China. Total loss to shareholders of 67% over the past three years. Annuncio • Sep 11
WuXi AppTec Co., Ltd. (SHSE:603259) announces an Equity Buyback for CNY 1,000 million worth of its shares. WuXi AppTec Co., Ltd. (SHSE:603259) announces a share repurchase program. Under the program, the company will repurchase up to CNY 1,000 million worth of its A shares. The shares will be repurchased at a price not more than CNY 61.02 per share. The purpose of the program is to safeguard the company's value and the interests of shareholders; and to enhance investor’s confidence. After the repurchase is completed, all the shares repurchased will be canceled and the registered capital will be reduced. The company will use its own funds to repurchase its shares. The program will be valid for a period of 3 months. Reported Earnings • Jul 30
Second quarter 2024 earnings released: EPS: CN¥0.79 (vs CN¥1.07 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.79 (down from CN¥1.07 in 2Q 2023). Revenue: CN¥9.26b (down 6.5% from 2Q 2023). Net income: CN¥2.30b (down 27% from 2Q 2023). Profit margin: 25% (down from 32% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Annuncio • Jun 28
WuXi AppTec Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024 WuXi AppTec Co., Ltd. announced that they will report first half, 2024 results on Jul 30, 2024 Declared Dividend • Jun 22
Dividend increased to CN¥0.99 Dividend of CN¥0.99 is 11% higher than last year. Ex-date: 26th June 2024 Payment date: 26th June 2024 Dividend yield will be 2.4%, which is higher than the industry average of 1.4%. Sustainability & Growth Dividend is well covered by both earnings (31% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 32% per year over the past 5 years. However, payments have been volatile during that time. EPS is expected to grow by 35% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annuncio • Jun 13
WuXi AppTec Co., Ltd. Approves Cash Dividend Payment for the Financial Year Ended 31 December 2023, Payable on July 5, 2024 WuXi AppTec Co., Ltd. approved cash dividend payment of RMB 9.8974 per 10 share for the financial year ended 31 December 2023 at its shareholders' meeting held on 12 June 2024. Ex-dividend date: 17 June 2024. Record date: 25 June 2024. Expected date of 2023 Profit Distribution is July 5, 2024. Annuncio • May 12
WuXi AppTec Co., Ltd., Annual General Meeting, Jun 12, 2024 WuXi AppTec Co., Ltd., Annual General Meeting, Jun 12, 2024, at 14:00 China Standard Time. Location: sheraton shanghai waigaoqiao hotel, 28 jilong road, pilot free trade zone, shanghai China Annuncio • May 10
Wuxi Apptec Co., Ltd. Proposes Final Cash Dividend Payment for the Financial Year Ended 31 December 2023 WuXi AppTec Co., Ltd. proposed final cash dividend payment of RMB 9.8336 per 10 share for the financial year ended 31 December 2023 at its shareholders' meeting to be held on 12 June 2024.Ex-dividend date: 17 June 2024. Record date: 25 June 2024. Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.74 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.65 (down from CN¥0.74 in 1Q 2023). Revenue: CN¥7.98b (down 11% from 1Q 2023). Net income: CN¥1.94b (down 10% from 1Q 2023). Profit margin: 24% (in line with 1Q 2023). Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Annuncio • Apr 30
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Full Year 2024 WuXi AppTec Co., Ltd. provided earnings guidance for full year of 2024. For the full year, the Company expects to deliver revenue of RMB 38.3 billion - RMB 40.5 billion. Annuncio • Mar 29
WuXi AppTec Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 WuXi AppTec Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Annuncio • Mar 20
WuXi AppTec Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023 WuXi AppTec Co., Ltd. proposed final ordinary dividend of RMB 9.8336 per 10 share for the year ended December 31, 2023. Reported Earnings • Mar 19
Full year 2023 earnings released: EPS: CN¥3.27 (vs CN¥3.01 in FY 2022) Full year 2023 results: EPS: CN¥3.27 (up from CN¥3.01 in FY 2022). Revenue: CN¥40.3b (up 2.5% from FY 2022). Net income: CN¥9.61b (up 9.0% from FY 2022). Profit margin: 24% (up from 22% in FY 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. New Risk • Feb 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.5% average weekly change). Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥59.36, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 20x in the Life Sciences industry in China. Total loss to shareholders of 58% over the past three years. Annuncio • Dec 29
WuXi AppTec Co., Ltd. to Report Fiscal Year 2023 Results on Mar 19, 2024 WuXi AppTec Co., Ltd. announced that they will report fiscal year 2023 results on Mar 19, 2024 Reported Earnings • Oct 31
Third quarter 2023 earnings released: EPS: CN¥0.94 (vs CN¥0.93 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.94 (up from CN¥0.93 in 3Q 2022). Revenue: CN¥10.7b (flat on 3Q 2022). Net income: CN¥2.76b (flat on 3Q 2022). Profit margin: 26% (in line with 3Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 01
Second quarter 2023 earnings released: EPS: CN¥1.07 (vs CN¥1.03 in 2Q 2022) Second quarter 2023 results: EPS: CN¥1.07 (up from CN¥1.03 in 2Q 2022). Revenue: CN¥9.91b (up 6.7% from 2Q 2022). Net income: CN¥3.14b (up 5.1% from 2Q 2022). Profit margin: 32% (in line with 2Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Annuncio • Jun 28
WuXi AppTec Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023 WuXi AppTec Co., Ltd. announced that they will report first half, 2023 results on Aug 01, 2023 Annuncio • Jun 07
WuXi AppTec Co., Ltd. Announces Executive Changes The board of directors of WuXi AppTec Co., Ltd. announced that Mr. Chi YAO has resigned as (i) a joint company secretary of the Company ("Joint Company Secretary"); The Board further announces that Mr. Yuanzhou ZHANG has been appointed as Joint Company Secretary, Authorised Representative and Process Agent in replacement of Mr. Yao with effect from June 6, 2023. Mr. Zhang, aged 34, holds a Master's degree and is a Chinese national. He currently serves as the Senior Director of the Mergers and Acquisitions Department of the Company. Mr. Zhang served as a Management Trainee and a Relationship Manager of the Global Banking Department in HSBC Bank (China) Company Limited from June 2013 to April 2016. From May 2016 to September 2018, he served as a Vice President of the Investment Banking Department in CSC Financial Co., Ltd. Since October 2018, Mr. Zhang has served various positions in the Company, including Investment Director of the Corporate Development and Investment Department, as well as Senior Director of the Mergers and Acquisitions Department. His primary responsibilities entail conducting industry mergers and acquisitions, equity investments and strategic collaborations which are aligned with core businesses of the Company. Mr. Zhang obtained a Bachelor's degree in Economics from the Central University of Finance and Economics. He also obtained a Master's degree in Finance from the Olin Business School at Washington University in St. Louis in the United States. Ms. CHEUNG Yuet Fan ("Ms. Cheung"), an existing joint company secretary of the Company, will continue with the role and act as the other Joint Company Secretary and Process Agent. Ms. Cheung is a director of Corporate Services of Tricor Services Limited, a global professional services provider specialising in integrated business, corporate and investor services. Ms. Cheung is a Chartered Secretary, a Chartered Governance Professional and a Fellow of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Ms. Cheung has over 25 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Cheung obtained a Bachelor of Arts degree in Accountancy from City Polytechnic of Hong Kong (now known as City University of Hong Kong) in November 1993. Annuncio • May 18
Wuxi AppTec Co., Ltd Announces Demise of Ning Zhao, Executive Director and Senior Vice President WuXi AppTec Co., Ltd. announced that Dr. Ning Zhao, the co-founder, one of the actual controllers, executive director and senior vice president of the Company, has passed away on May 16, 2023. Dr. Zhao was an extraordinary scientist, leader and philanthropist with an unwavering commitment to improving human health. She obtained her bachelor's degree in chemistry from Peking University, doctoral degree in organic chemistry from Columbia University, and then began her remarkable career with top organizations, advancing through the ranks of research and management. As one of our co-founders, Dr. Zhao played an instrumental role in shaping our Company into what it is today. She built our integrated bioanalytical capabilities with global regulatory standards a cornerstone of our testing platform and CRDMO/CTDMO model today. She also spearheaded the Company's talent development strategies and HR transformations that have become award-winning industry best practices. Reported Earnings • Mar 21
Full year 2022 earnings released: EPS: CN¥3.01 (vs CN¥1.75 in FY 2021) Full year 2022 results: EPS: CN¥3.01 (up from CN¥1.75 in FY 2021). Revenue: CN¥39.4b (up 72% from FY 2021). Net income: CN¥8.81b (up 73% from FY 2021). Profit margin: 22% (in line with FY 2021). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Annuncio • Jan 31
Wuxi Apptec Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022 WuXi AppTec Co., Ltd. provided earnings guidance for the year ended December 31, 2022. The company is expecting to record an increase in the revenue and net profit attributable to shareholders of the Company for the year ended December 31, 2022 in comparison with the corresponding period in the year of 2021. Buying Opportunity • Dec 20
Now 21% undervalued Over the last 90 days, the stock is up 4.7%. The fair value is estimated to be CN¥95.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 35% over the last 3 years. Earnings per share has grown by 48%. For the next 3 years, revenue is forecast to grow by 19% per annum. Earnings is also forecast to grow by 15% per annum over the same time period. Buying Opportunity • Nov 23
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 5.5%. The fair value is estimated to be CN¥106, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 35% over the last 3 years. Earnings per share has grown by 48%. For the next 3 years, revenue is forecast to grow by 19% per annum. Earnings is also forecast to grow by 15% per annum over the same time period. Buying Opportunity • Nov 09
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be CN¥106, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 35% over the last 3 years. Earnings per share has grown by 48%. For the next 3 years, revenue is forecast to grow by 19% per annum. Earnings is also forecast to grow by 16% per annum over the same time period. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.93 (vs CN¥0.30 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.93 (up from CN¥0.30 in 3Q 2021). Revenue: CN¥10.6b (up 78% from 3Q 2021). Net income: CN¥2.74b (up 209% from 3Q 2021). Profit margin: 26% (up from 15% in 3Q 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥80.96, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 35x in the Life Sciences industry in China. Total returns to shareholders of 61% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥118 per share. Reported Earnings • Jul 29
Second quarter 2022 earnings released: EPS: CN¥1.03 (vs CN¥0.40 in 2Q 2021) Second quarter 2022 results: EPS: CN¥1.03 (up from CN¥0.40 in 2Q 2021). Revenue: CN¥9.28b (up 66% from 2Q 2021). Net income: CN¥2.99b (up 155% from 2Q 2021). Profit margin: 32% (up from 21% in 2Q 2021). Over the next year, revenue is forecast to grow 41%, compared to a 45% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 41% per year whereas the company’s share price has increased by 36% per year. Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥105, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 43x in the Life Sciences industry in China. Total returns to shareholders of 210% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥168 per share. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: CN¥0.56 (vs CN¥0.52 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.56 (up from CN¥0.52 in 1Q 2021). Revenue: CN¥8.47b (up 71% from 1Q 2021). Net income: CN¥1.64b (up 9.5% from 1Q 2021). Profit margin: 19% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 52%, compared to a 42% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. 5 independent directors (7 non-independent directors). Independent Non-Executive Director Feng Dai was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Buying Opportunity • Apr 07
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be CN¥135, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 29% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings is also forecast to grow by 24% per annum over the same time period. Reported Earnings • Feb 17
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CN¥1.75 (up from CN¥1.06 in FY 2020). Revenue: CN¥22.9b (up 39% from FY 2020). Net income: CN¥5.10b (up 73% from FY 2020). Profit margin: 22% (up from 18% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 62%, compared to a 49% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 41% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥85.86, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 45x in the Life Sciences industry in China. Total returns to shareholders of 149% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥156 per share. Buying Opportunity • Jan 20
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 20%. The fair value is estimated to be CN¥140, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% per annum over the last 3 years. Earnings per share has grown by 19% per annum over the last 3 years. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.23 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥5.98b (up 31% from 3Q 2020). Net income: CN¥887.1m (up 36% from 3Q 2020). Profit margin: 15% (in line with 3Q 2020). Recent Insider Transactions • Sep 30
Key Executive recently sold CN¥5.3m worth of stock On the 27th of September, Edward Hu sold around 35k shares on-market at roughly CN¥153 per share. This was the largest sale by an insider in the last 3 months. This was Edward's only on-market trade for the last 12 months. Recent Insider Transactions • Sep 22
Co-CEO & Executive Director recently sold CN¥2.8m worth of stock On the 14th of September, Yang Qing sold around 20k shares on-market at roughly CN¥141 per share. This was the largest sale by an insider in the last 3 months. Yang has been a seller over the last 12 months, reducing personal holdings by CN¥5.7m. Recent Insider Transactions • Sep 03
Co-Chief Executive Officer recently sold CN¥1.1m worth of stock On the 30th of August, Chen Minzhang sold around 9k shares on-market at roughly CN¥130 per share. This was the largest sale by an insider in the last 3 months. This was Chen's only on-market trade for the last 12 months. Reported Earnings • Aug 14
Second quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.51 in 2Q 2020) The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥5.59b (up 38% from 2Q 2020). Net income: CN¥1.18b (down 17% from 2Q 2020). Profit margin: 21% (down from 35% in 2Q 2020). The decrease in margin was driven by higher expenses. Annuncio • Jul 16
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2021 WuXi AppTec Co., Ltd. provided earnings guidance for the six months ended June 30, 2021. The board of directors of the Company announced that the Company is expecting to record an increase in the net profit attributable to shareholders of the Company for the six months ended June 30, 2021 in comparison with the corresponding period of 2020. The net profit attributable to shareholders of the Company was estimated to increase by a range between RMB 910.0924 million to RMB 944.4355 million for the first half of 2021. Annuncio • May 15
WuXi AppTec Co., Ltd. Approves the 2020 Profit Distribution Plan WuXi AppTec Co., Ltd. at its AGM held on May 13, 2021 approved that, the company will issue two 2020 Capitalization Shares for every existing ten Shares by way of capitalization of reserve, and will pay a cash dividend in an aggregate amount of RMB 889,579,996,437 (inclusive of tax) (representing a dividend of RMB3.63 (inclusive of tax) per ten Shares based on the total issued Shares as at the date of this announcement) to the Shareholders whose names appear on the register of members of the Company on June 7, 2021 (the "Record Date"). The New Capitalization H Shares will be issued on a pro-rated basis and any fractional Shares (if any) will be rounded down to the nearest whole unit. No fractional Shares will be issued and distributed pursuant to the 2020 Capitalization of Reserve, but will be aggregated and sold for the benefit of the Company. The cash dividend will also be paid on a pro-rated basis for Shareholders who hold Shares in odd lot (i.e. RMB 0.363 per ordinary Share). The 2020 Profit Distribution will be declared according to the Articles of Association. Dividend on A Shares will be paid in Renminbi and dividend on H Shares will be paid in Hong Kong dollars. The exchange rate to be used to convert the cash dividend from RMB to HKD will be the average of the medium rate of RMB to HKD announced by the People's Bank of China for five working days prior to and including May 13, 2021, the date on which the 2020 Profit Distribution was declared at the 2020 AGM. The Company has appointed a receiving agent to whom the 2020 Profit Distribution will be paid for their onward payment to the H Shareholders. Expected date of 2020 Profit Distribution for June 17, 2021 H Shareholders. Reported Earnings • May 02
First quarter 2021 earnings released: EPS CN¥0.62 (vs CN¥0.13 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥4.95b (up 55% from 1Q 2020). Net income: CN¥1.50b (up 395% from 1Q 2020). Profit margin: 30% (up from 9.5% in 1Q 2020). The increase in margin was driven by higher revenue. Annuncio • Apr 30
WuXi AppTec Co., Ltd. Provides Revenue Guidance for the Second Half of 2021 WuXi AppTec Co., Ltd. provided strong rebound in revenue growth in the second half of 2021. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥1.27 (vs CN¥0.81 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥16.5b (up 28% from FY 2019). Net income: CN¥2.96b (up 60% from FY 2019). Profit margin: 18% (up from 14% in FY 2019). The increase in margin was driven by higher revenue. Annuncio • Mar 17
WuXi AppTec Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021 WuXi AppTec Co., Ltd. announced that they will report fiscal year 2020 results on Mar 30, 2021 Reported Earnings • Mar 07
Full year 2020 earnings released: EPS CN¥1.27 (vs CN¥0.81 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥16.5b (up 28% from FY 2019). Net income: CN¥2.96b (up 60% from FY 2019). Profit margin: 18% (up from 14% in FY 2019). The increase in margin was driven by higher revenue. Analyst Estimate Surprise Post Earnings • Mar 07
Revenue beats expectations Revenue exceeded analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 29%, compared to a 32% growth forecast for the Life Sciences industry in China. Annuncio • Feb 13
Quanterix Corporation and WuXi AppTec Enter into an Agreement to Open Joint Simoa Laboratory Quanterix Corporation announced that it has entered into an agreement to open a joint Simoa laboratory with WuXi AppTec to improve access to Quanterix’ industry leading biomarker testing and development offerings across China and the APAC market. The Simoa® Joint Lab is the strategic partnership between the two companies and will be established at WuXi AppTec’s Shanghai facility. The facility will leverage Quanterix’ ultra-sensitive Simoa HD-X Analyzers™, consumables resources and technical expertise to advance essential pre-clinical and clinical research in the region. Starting in 2021, APAC researchers across academia, private research firms and biopharmaceuticals organizations will be able to access Quanterix’ high-definition Simoa technology and suite of custom biomarker testing, development and validation services offered through the Simoa Joint Lab in Shanghai. This model will be based off the company’s state-of-the-art Accelerator Lab at their headquarters in Billerica, MA. The Quanterix’ flagship research facility that has tested more than 100,000 samples for over 800 projects, powering the research of more than 200 companies and accelerating drug approval timelines through the detection of proteins and nucleic acids at the lowest possible levels. Is New 90 Day High Low • Feb 11
New 90-day high: CN¥185 The company is up 57% from its price of CN¥118 on 13 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 49% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥120 per share. Is New 90 Day High Low • Jan 20
New 90-day high: CN¥154 The company is up 48% from its price of CN¥104 on 23 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥88.65 per share. Is New 90 Day High Low • Dec 17
New 90-day high: CN¥123 The company is up 27% from its price of CN¥96.58 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥71.36 per share. Is New 90 Day High Low • Nov 05
New 90-day high: CN¥115 The company is up 3.0% from its price of CN¥112 on 07 August 2020. The Chinese market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥59.28 per share. Annuncio • Oct 30
WuXi AppTec Co., Ltd. (SHSE:603259) acquired Milestone Pharma. WuXi AppTec Co., Ltd. (SHSE:603259) acquired Milestone Pharma during the period ended September 30, 2020.
WuXi AppTec Co., Ltd. (SHSE:603259) completed the acquisition of Milestone Pharma during the period ended September 30, 2020. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥2.46b, up 17% from the prior year. Total revenue was CN¥15.4b over the last 12 months, up 29% from the prior year. Annuncio • Oct 16
WuXi AppTec Co., Ltd. to Report Q3, 2020 Results on Oct 29, 2020 WuXi AppTec Co., Ltd. announced that they will report Q3, 2020 results at 11:30 PM, GMT Standard Time on Oct 29, 2020 Annuncio • Sep 26
WuXi AppTec Co., Ltd. announced that it has received CNY 6.527939898 billion in funding from a group of investors On September 7, 2020, WuXi AppTec Co., Ltd. (SHSE:603259) closed the transaction. The company issued 62,690,290 shares at a price of CNY 104.13 per share for gross proceeds of CNY 6,527,939,897.70 in the transaction. The transaction included participation from 17 investors including Beixin Ruifeng Fund Management Co., Ltd. for CNY 999,999,959.40, UBS AG for CNY 1,505,999,909.70, Merrill Lynch International for CNY 917,940,625.29, individual investors Hong Tao for CNY 199,999,991.88 and Gao Jinhua for CNY 229,999,949.01. On September 23, 2020, the company completed the registration procedures for the newly issued shares at China Securities Depository and Clearing Co., Ltd. Shanghai Branch. Annuncio • Sep 25
WuXi AppTec Co., Ltd. announced that it expects to receive CNY 6.52794 billion in funding from a group of investors WuXi AppTec Co., Ltd. (SHSE:603259) announced a private placement of not more than 75,000,000 A shares for gross proceeds of not more than CNY 6,527,940,000 on March 24, 2020. The transaction will include participation from not more than 35 specific investors including securities investment fund management companies, securities companies, trust companies, finance companies and insurance institutional investors and qualified foreign institutional investors and other legal persons, natural persons or other institutional investors. The issuance price will be not lower than 80% of the average price of the company’s shares as of 20 trading days since issuance date. The shares will be issued at premium to nominal value of CNY 1 per share. The total number A shares will increase from 1,480,612,971 shares to 1,555,512,971 shares. The A shares are subject to lock-up period of 6 months from issuance. The transaction is approved in the 39th meeting of the 1st directorate, 2019 annual board meeting, and 27th meeting of 1st supervisory board of the company. The transaction is subject to approval of shareholders of the company at its annual general meeting, China Securities Regulatory Commission, Shanghai Stock Exchange, and the Shanghai Branch of China Securities Depository and Clearing Corporation Limited. 
